Miguel Ángel Seguí

3.9k total citations
83 papers, 1.4k citations indexed

About

Miguel Ángel Seguí is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Miguel Ángel Seguí has authored 83 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 41 papers in Cancer Research and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Miguel Ángel Seguí's work include Breast Cancer Treatment Studies (38 papers), Cancer Treatment and Pharmacology (36 papers) and HER2/EGFR in Cancer Research (25 papers). Miguel Ángel Seguí is often cited by papers focused on Breast Cancer Treatment Studies (38 papers), Cancer Treatment and Pharmacology (36 papers) and HER2/EGFR in Cancer Research (25 papers). Miguel Ángel Seguí collaborates with scholars based in Spain, United States and Germany. Miguel Ángel Seguí's co-authors include Aňa Lluch, Montserrat Muñoz-Mateu, Lourdes Calvo, Miguel Martín, A. Antón, Àngels Arcusa, Álvaro Rodríguez-Lescure, Ignasi Tusquets, Isabel Álvarez and Encarna Adrover and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Miguel Ángel Seguí

78 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Miguel Ángel Seguí Spain	22	889	444	267	228	134	83	1.4k
Roberta Maltoni Italy	21	722 0.8×	376 0.8×	338 1.3×	299 1.3×	99 0.7×	84	1.2k
Laura Pizzuti Italy	23	906 1.0×	410 0.9×	454 1.7×	333 1.5×	140 1.0×	96	1.7k
P. Hupperets Netherlands	21	629 0.7×	340 0.8×	328 1.2×	266 1.2×	165 1.2×	40	1.4k
Kristina Lindemann Norway	25	748 0.8×	327 0.7×	452 1.7×	222 1.0×	151 1.1×	111	2.1k
Chantal Bernard-Marty Belgium	14	845 1.0×	441 1.0×	280 1.0×	247 1.1×	96 0.7×	22	1.2k
Phuong K. Morrow United States	24	1.0k 1.2×	283 0.6×	525 2.0×	396 1.7×	181 1.4×	65	1.8k
Laura Kruper United States	18	825 0.9×	580 1.3×	300 1.1×	187 0.8×	155 1.2×	66	1.7k
Amy Tiersten United States	20	1.0k 1.1×	275 0.6×	264 1.0×	324 1.4×	96 0.7×	101	1.6k
Mireia Margelí Vila Spain	20	784 0.9×	485 1.1×	440 1.6×	416 1.8×	127 0.9×	94	1.4k
Gary V. Burton United States	23	732 0.8×	422 1.0×	209 0.8×	339 1.5×	199 1.5×	68	1.5k

Countries citing papers authored by Miguel Ángel Seguí

Since Specialization

Citations

This map shows the geographic impact of Miguel Ángel Seguí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel Ángel Seguí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel Ángel Seguí more than expected).

Fields of papers citing papers by Miguel Ángel Seguí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel Ángel Seguí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel Ángel Seguí. The network helps show where Miguel Ángel Seguí may publish in the future.

Co-authorship network of co-authors of Miguel Ángel Seguí

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel Ángel Seguí. A scholar is included among the top collaborators of Miguel Ángel Seguí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel Ángel Seguí. Miguel Ángel Seguí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Navarro‐Sabaté, Àurea, Rebeca Font, Josep Alfons Espinàs, et al.. (2025). Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?. Cancers. 17(2). 200–200. 1 indexed citations

Gavilá, Joaquín, et al.. (2025). Do patients with HER2+ MBC and their HCPs speak the same language? Perceptions and uses of chronic disease and metastatic treatment arising from the EtnobreastHER2 study. Patient Education and Counseling. 140. 109289–109289.

Godoy-Ortíz, Ana, et al.. (2024). Exercise in cancer patients: assistance levels and referral pathways—a position statement from the Spanish Society of Medical Oncology. Clinical & Translational Oncology. 27(1). 108–116. 3 indexed citations

Blanch, Salvador, Miguel Gil‐Gil, Míriam Arumí, et al.. (2023). Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS). Clinical & Translational Oncology. 25(10). 2950–2959. 4 indexed citations

Pérez-García, José Manuel, Antonio Llombart‐Cussac, María Gión, et al.. (2021). Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial. European Journal of Cancer. 148. 382–394. 30 indexed citations

Kolberg, Hans‐Christian, Marco Colleoni, Patrícia Xavier Santi, et al.. (2019). Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Targeted Oncology. 14(6). 647–656. 12 indexed citations

Hernández, Vanessa, Núria Baixeras, Daniel Cuadras, et al.. (2017). Predictive and Prognostic Brain Metastases Assessment in Luminal Breast Cancer Patients: FN14 and GRP94 from Diagnosis to Prophylaxis. Frontiers in Oncology. 7. 283–283. 11 indexed citations

Losa, Ferrán, G. Soler, Antonio Casado, et al.. (2017). SEOM clinical guideline on unknown primary cancer (2017). Clinical & Translational Oncology. 20(1). 89–96. 41 indexed citations

Martín, Miguel, Jan C. Brase, Amparo Ruı́z, et al.. (2016). Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Research and Treatment. 156(1). 81–89. 35 indexed citations

10.

Ruiz, Anna, Gemma Llort, Neus Baena, et al.. (2014). Genetic Testing in Hereditary Breast and Ovarian Cancer Using Massive Parallel Sequencing. BioMed Research International. 2014. 1–8. 13 indexed citations

11.

Rojo, Federico, Aňa Lluch, Amparo Ruı́z, et al.. (2014). Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel.. Journal of Clinical Oncology. 32(15_suppl). 11107–11107. 1 indexed citations

12.

Sánchez‐Rovira, Pedro, Miguel Ángel Seguí, Antonio Llombart‐Cussac, et al.. (2013). Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clinical & Translational Oncology. 15(10). 810–817. 9 indexed citations

13.

Crespo, Carlos, et al.. (2013). Head to Head Economic Evaluation of Two Genomic Profiles of Recurrence Risk for Breast Cancer, Mammaprint Versus Oncotype DX, in Spain. Value in Health. 16(7). A416–A417.

14.

Antón, A., A. Ruíz, Arrate Plazaola, et al.. (2010). Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Annals of Oncology. 22(1). 74–79. 27 indexed citations

15.

García‐Estévez, Laura, Ignasi Tusquets, Montse Muñoz, et al.. (2007). Advanced breast cancer: chemotherapy phase III trials that change a standard. Anti-Cancer Drugs. 18(7). 843–859. 8 indexed citations

16.

Andreu, F., et al.. (2005). HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—A study of two hundred cases. The Breast. 15(4). 519–527. 54 indexed citations

17.

Vadell, Catalina, Miguel Ángel Seguí, Serafín Morales, et al.. (1998). Anticachectic Efficacy of Megestrol Acetate at Different Doses and Versus Placebo in Patients With Neoplastic Cachexia. American Journal of Clinical Oncology. 21(4). 347–351. 41 indexed citations

18.

Seguí, Miguel Ángel, et al.. (1998). Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. Cancer. 83(2). 254–258. 2 indexed citations

19.

Saigí, Eugeni, et al.. (1995). Clinical Experience with Tegafur and Low Dose Oral Leucovorin: A Dose-Finding Study. Oncology. 52(2). 167–169. 5 indexed citations

20.

Seguí, Miguel Ángel, et al.. (1993). [The clinico-mammographic follow-up of breast cancer after conservative treatment].. PubMed. 192(7). 309–14. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact